Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago.
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
Here's Why Agios Stock Plummeted More Than 20% on Monday
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
4 Medical Product Stocks to Buy From a Prospective Industry
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd's label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025.
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to
